scholarly journals Improved Survival With Integration of Chinese Herbal Medicine Therapy in Patients With Acute Myeloid Leukemia: A Nationwide Population-Based Cohort Study

2016 ◽  
Vol 16 (2) ◽  
pp. 156-164 ◽  
Author(s):  
Tom Fleischer ◽  
Tung-Ti Chang ◽  
Jen-Huai Chiang ◽  
Mao-Feng Sun ◽  
Hung-Rong Yen
Keyword(s):  
Acute Myeloid Leukemia ◽  
Cohort Study ◽  
Herbal Medicine ◽  
Chinese Herbal Medicine ◽  
Myeloid Leukemia ◽  
Salvia Miltiorrhiza ◽  
Population Based ◽  
Research Database ◽  
Chinese Herbal ◽  
Acute Myeloid

Purpose. Acute myeloid leukemia (AML) is the most deadly subtype of leukemia, and many patients with this disease seek other complementary therapies, one of which is Chinese medicine. We set out to provide reliable data regarding the benefit of Chinese herbal medicine (CHM) for AML patients, using mortality as the main outcome measure. We also characterized the herbal prescriptions of patients. Methods. Using the Taiwanese National Health Insurance Research Database, we performed a nationwide population-based cohort study among AML patients from 1997 to 2010. The Cox regression model was used to adjust for comorbidities and other variables, and the hazard ratios (HRs) of CHM users and non–CHM users were compared. Results. After 1:1 matching, 498 patients were included into the study. The HR of the CHM group was 0.41 (95% CI = 0.26-0.65; P = .0001) compared with the non-CHM group. This decrease in HR was also shown to be dose dependent ( P < .001). The 3 single-herbs most commonly prescribed were Salvia miltiorrhiza (Dan Shen), Astragalus membranaceus (Huang Qi), and Spatholobus suberectus (Ji Xue Teng). The 3 mutli-herb products most commonly prescribed were Jia Wei Xiao Yao San, Gui Pi Tang, and Qi Ju Di Huang Wan. Conclusion. Prospective controlled clinical data is still needed, however, this study provides real-world data regarding the benefit AML patients may have from CHM. This study suggests that all AML patients, regardless of age or other prognostic factors, may achieve longer survival times when receiving CHM in addition to standard therapy.

scholarly journals Chinese Herbal Medicine as an Adjunctive Therapy Ameliorated the Incidence of Chronic Hepatitis in Patients with Breast Cancer: A Nationwide Population-Based Cohort Study

2017 ◽  
Vol 2017 ◽  
pp. 1-9 ◽  
Author(s):  
Kuo-Chin Huang ◽  
Hung-Rong Yen ◽  
Jen-Huai Chiang ◽  
Yuan-Chih Su ◽  
Mao-Feng Sun ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Chronic Hepatitis ◽  
Cohort Study ◽  
Herbal Medicine ◽  
Incidence Rate ◽  
Chinese Herbal Medicine ◽  
Therapeutic Potential ◽  
Population Based ◽  
Research Database ◽  
Chinese Herbal

We conducted a National Health Insurance Research Database-based Taiwanese nationwide population-based cohort study to evaluate whether Chinese herbal medicine (CHM) treatment decreased the incidence of chronic hepatitis in breast cancer patients receiving chemotherapy and/or radiotherapy. A total of 81171 patients were diagnosed with breast cancer within the defined study period. After randomly equal matching, data from 13856 patients were analyzed. Hazard ratios of incidence rate of chronic hepatitis were used to determine the influence and therapeutic potential of CHM in patients with breast cancer. The patients with breast cancer receiving CHM treatment exhibited a significantly decreased incidence rate of chronic hepatitis even across the stratification of age, CCI score, and treatments. The cumulative incidence of chronic hepatitis for a period of seven years after initial breast cancer diagnosis was also reduced in the patients receiving CHM treatment. The ten most commonly used single herbs and formulas were effective in protecting liver function in patients with breast cancer, where Hedyotis diffusa and Jia-Wei-Xiao-Yao-San were the most commonly used herbal agents. In conclusion, our study provided information that western medicine therapy combined with CHM as an adjuvant modality may have a significant impact on liver protection in patients with breast cancer.

scholarly journals Adjunctive Chinese Herbal Medicine therapy improves survival of patients with chronic myeloid leukemia: a nationwide population‐based cohort study

2016 ◽  
Vol 5 (4) ◽  
pp. 640-648 ◽  
Author(s):  
Tom Fleischer ◽  
Tung‐Ti Chang ◽  
Jen‐Huai Chiang ◽  
Ching‐Mao Chang ◽  
Ching‐Yun Hsieh ◽  
...  
Keyword(s):  
Cohort Study ◽  
Chronic Myeloid Leukemia ◽  
Herbal Medicine ◽  
Chinese Herbal Medicine ◽  
Myeloid Leukemia ◽  
Population Based ◽  
Chinese Herbal

scholarly journals Association Between Chinese Herbal Medicine Therapy and the Risk of Chronic Kidney Disease in Gout Patients

2021 ◽  
Vol 12 ◽  
Author(s):  
Yan-Zhuan Xiao ◽  
Zhi-Zhong Ye ◽  
Yuan-Tong Liang ◽  
Xin-Peng Chen ◽  
Yu-Hsun Wang ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Herbal Medicine ◽  
Chinese Herbal Medicine ◽  
Conditional Logistic Regression ◽  
International Classification Of Diseases ◽  
Population Based ◽  
Research Database ◽  
Chinese Herbal ◽  
Incidence Of Ckd

Background: Chinese herbal medicine (CHM) has been nationally and globally used in treating gout for over a millennium. The potential relationship between the incidence of chronic kidney disease (CKD) in gout patients and CHM therapy is unclear. Thus, this study aimed to provide some evidence regarding the relationship between CHM therapy and the occurrence of CKD in gout patients.Methods: We used data from the National Health Insurance Research database (NHIRD) in Taiwan. In this population-based nested case-control study, all participants were identified by International Classification of Diseases, Ninth Revision (ICD-9). Conditional logistic regression was used to calculate the odds ratio (OR) of the risk of CKD in gout patients treated with CHM therapy.Results: Data on 1718 gout patients with CKD and 1:1 matched 1718 gout patients without CKD were collected for analysis. The results showed that CHM therapy in gout patients did not increase the risk of developing CKD (adjusted OR = 1.01; 95% confidence interval [CI]: 0.86–1.18; p &gt; 0.05). Moreover, CHM therapy in gout patients for &gt;365 days did not increase the incidence of CKD (adjusted OR = 1.30; 95% CI: 0.90–1.88; p = 0.162).Conclusion: Traditional CHM therapy does not increase the incidence of CKD in gout patients.

scholarly journals Chinese herbal medicine use in Taiwan during pregnancy and the postpartum period: A population-based cohort study

2009 ◽  
Vol 46 (6) ◽  
pp. 787-795 ◽  
Author(s):  
Chao-Hua Chuang ◽  
Pei-Jen Chang ◽  
Wu-Shiun Hsieh ◽  
Yih-Jian Tsai ◽  
Shio-Jean Lin ◽  
...  
Keyword(s):  
Cohort Study ◽  
Herbal Medicine ◽  
Chinese Herbal Medicine ◽  
Postpartum Period ◽  
Population Based ◽  
Medicine Use ◽  
Chinese Herbal

scholarly journals Chinese Herbal Medicine Therapy Reduces the Risks of Overall and Anemia-Related Mortalities in Patients With Aplastic Anemia: A Nationwide Retrospective Study in Taiwan

2021 ◽  
Vol 12 ◽  
Author(s):  
Mu-Lin Chiu ◽  
Yu-Lung Hsu ◽  
Chao-Jung Chen ◽  
Te-Mao Li ◽  
Jian-Shiun Chiou ◽  
...  
Keyword(s):  
Herbal Medicine ◽  
Aplastic Anemia ◽  
Chinese Herbal Medicine ◽  
Large Scale ◽  
Salvia Miltiorrhiza ◽  
Bone Marrow Failure ◽  
Complementary Therapy ◽  
Population Based ◽  
Chinese Herbal ◽  
Kaplan Meier

Aplastic Anemia (AA) is a rare but fatal hematologic disease that may occur at any age and especially higher in Asia. We investigated whether Chinese herbal medicine (CHM) is beneficial to AA patients as a complementary therapy using a nationwide population-based database in Taiwan between 2000–2016. Patient survival was estimated by Kaplan‒Meier survival analyses and Cox proportional-hazard model. CHM-users presented lower risks of overall and anemia-related mortalities when compared to non-users. The risk of overall mortality for CHM-users in AA patients was 0.70-fold [adjusted hazard ratio (aHR): 0.70, 95% confidence interval (CI): 0.66-0.74, p &lt; 0.001). The risk of anemia-related mortality was lower in CHM-users when compared to non-users (aHR: 0.46, 95% CI: 0.32-0.67, p &lt; 0.001). The association rule analysis revealed that CHM pairs were Ban-Zhi-Lian (BZL; Scutellaria barbata D. Don)→Bai-Hua-She-She-Cao (BHSSC; Oldenlandia diffusa (Willd.) Roxb.), followed by Dang-Gui (DG; Angelica sinensis (Oliv.) Diels)→Huang-Qi (HQi; Astragalus membranaceus (Fisch.) Bunge), and Xian-He-Cao (XHC; Agrimonia pilosa f. borealis (Kitag.) Chu)→Gui-Pi-Tang (GPT). Network analysis showed that BZL, BHSSC, DG, HQi, XHC, GPT, and Dan-Shen (DanS; Salvia miltiorrhiza var. charbonnelii (H.Lév.) C.Y.Wu) were commonly used CHMs for AA patients. Therefore, further studies for these commonly prescribed herbs are needed in functional investigations in hematopoiesis-stimulating effect and large-scale randomized controlled trials (RCT) in bone marrow failure related diseases.

scholarly journals Improved outcome in acute myeloid leukemia patients enrolled in clinical trials: A national population-based cohort study of Danish intensive chemotherapy patients

Oncotarget ◽  
2016 ◽  
Vol 7 (44) ◽  
pp. 72044-72056 ◽  
Author(s):  
Lene Sofie Granfeldt Østgård ◽  
Mette Nørgaard ◽  
Henrik Sengeløv ◽  
Bruno C. Medeiros ◽  
Lars Kjeldsen ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Acute Myeloid Leukemia ◽  
Cohort Study ◽  
Myeloid Leukemia ◽  
Population Based ◽  
Intensive Chemotherapy ◽  
National Population ◽  
Chemotherapy Patients ◽  
Improved Outcome ◽  
Acute Myeloid
Sign in / Sign up

Export Citation Format

Share Document